{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:27:27Z","timestamp":1789644447287,"version":"4.0.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) is associated with high mortality rates. Despite antibiotic therapy, persistent bacteremia is challenging to treat. Combination therapy with ceftaroline has emerged as a potential treatment option; however, the optimal duration and clinical implications after bacteremia clearance are unknown.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective cohort study examined patients with high-grade or persistent MRSA bacteremia who were treated with ceftaroline combination therapy at the University of New Mexico Hospital between January 2014 and June 2021. Patients were categorized into short- (&lt;7 days) or long-duration (\u22657 days) groups based on the duration of combination therapy after bacteremia clearance. Outcomes included 30-day all-cause mortality, bacteremia recurrence, post-bacteremia clearance length of stay, and adverse events.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 32 patients were included in this study. The most common sources of bacteremia were bone\/joint and endovascular (28.1%, 9\/32 each). The median duration of combination therapy after clearance was seven days (IQR 2.8, 11). Patients in the long-duration group had a lower Charlson comorbidity index (1.0 vs 5.5, p = 0.017) than those in the short-duration group. After adjusting for confounders, there was no significant difference in the 30-day all-cause mortality between the groups (AOR 0.17, 95% CI 0.007\u20131.85, p = 0.18). No association was found between combination therapy duration and recurrence (OR 2.53, 95% CI 0.19\u2013inf, p = 0.24) or adverse drug events (OR 3.46, 95% CI 0.39\u201374.86, p = 0.31). After controlling for total hospital length of stay, there was no significant difference in the post-bacteremia clearance length of stay between the two groups (p = 0.37).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Prolonging ceftaroline combination therapy after bacteremia clearance did not significantly improve outcomes in patients with persistent or high-grade MRSA bacteremia. The limitations of this study warrant cautious interpretation of its results. Larger studies are needed to determine the optimal duration and role of combination therapy for this difficult-to-treat infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0304103","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:30:19Z","timestamp":1716226219000},"page":"e0304103","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5402-0240","authenticated-orcid":true,"given":"M. Gabriela","family":"Cabanilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Bernauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana M.","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Briski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Koury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7569-7496","authenticated-orcid":true,"given":"Chelsea N.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Jakeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"pone.0304103.ref001","first-page":"362","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"SJ Hal","year":"2021","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pone.0304103.ref002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"H Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pone.0304103.ref003","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1473-3099(14)70876-X","article-title":"A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bactaraemia: an observational cohort study","volume":"14","author":"LK Yaw","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"pone.0304103.ref004","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1001\/archinte.162.19.2229","article-title":"Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"162","author":"SI Blot","year":"2002","journal-title":"Arch Intern Med"},{"key":"pone.0304103.ref005","unstructured":"\u201cMRSA: Preventing Infections in Healthcare.\u201d Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP). 24 Jan. 2020, https:\/\/www.cdc.gov\/mrsa\/healthcare\/inpatient.html#:~:text=CDC%20estimates%20that%20MRSA%20is%20responsible%20for%20more,priority%20in%20healthcare%20facilities%3A%20assess%20your%20facility%E2%80%99s%20data%2C. Accessed July 25, 2022."},{"issue":"2","key":"pone.0304103.ref006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MD.0b013e318289ff1e","article-title":"Persistent Staphylococcus aureus bacteremia","volume":"92","author":"YP Chong","year":"2013","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0304103.ref007","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0304103.ref008","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","article-title":"Defining persistent Staphylococcus aureus bacteremia: secondary analysis of a prospective cohort study","volume":"20","author":"R Kuehl","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pone.0304103.ref009","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"SYC Tong","year":"2020","journal-title":"JAMA"},{"key":"pone.0304103.ref010","unstructured":"US Department of Health and Human Services, Health Resources and Services Administration. MUA (Medically Underserved Areas) Find. http:\/\/muafind.hrsa.gov\/index.aspx. Accessed July 28, 2023."},{"key":"pone.0304103.ref011","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cid\/ciac364","article-title":"Persistent methicillin-resistant Staphylococcus aureus bacteremia: resetting the clock for optimal management","volume":"75","author":"TL Holland","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0304103.ref012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00365540500372846","article-title":"Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome","volume":"38","author":"R Khatib","year":"2006","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"pone.0304103.ref013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/jac\/dkq050","article-title":"Predictors of persistent methicillin-resistant staphylococcus aureus bacteraemia in patients treated with vancomycin","volume":"65","author":"YK Yoon","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"pone.0304103.ref014","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"Beta-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"TJ Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0304103.ref015","doi-asserted-by":"crossref","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"M Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pone.0304103.ref016","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early Administration of Adjuvant \u03b2-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis","volume":"37","author":"REACH-ID Study Group","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"1","key":"pone.0304103.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz746","article-title":"Daptomycin plus beta lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","volume":"71","author":"SCJ Jorgensen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0304103.ref018","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"G Sakoulas","year":"2014","journal-title":"Clin Ther"},{"issue":"2","key":"pone.0304103.ref019","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"RA Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"pone.0304103.ref020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/1060028016664361","article-title":"Ceftaroline as salvage monotherapy for persistent MRSA bacteremia","volume":"50","author":"YJ Burnett","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0304103.ref021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/phar.2741","article-title":"Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"43","author":"WD Kufel","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"3","key":"pone.0304103.ref022","doi-asserted-by":"crossref","first-page":"106735","DOI":"10.1016\/j.ijantimicag.2023.106735","article-title":"Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia","volume":"61","author":"D Patel","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"pone.0304103.ref023","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1086\/502156","article-title":"Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity","volume":"24","author":"O Lesens","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"pone.0304103.ref024","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1086\/317421","article-title":"Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort","volume":"31","author":"JM Mylotte","year":"2000","journal-title":"Clin Infect Dis"},{"key":"pone.0304103.ref025","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1038\/s41598-018-26277-9","article-title":"Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility","volume":"8","author":"CC Yang","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0304103.ref026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2017.05.010","article-title":"Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"P Ayau","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0304103.ref027","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments","volume":"7","author":"EK McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"pone.0304103.ref028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for MRSA bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"JS Davis","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0304103.ref029","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40121-020-00292-8","article-title":"Monotherapy with vancomycin or daptomycin versus combination therapy with beta-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis","volume":"9","author":"S Alosaimy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"pone.0304103.ref030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"C Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0304103.ref031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/antibiotics12030455","article-title":"Persistent methicillin-resistant staphylococcus aureus bacteremia: host, pathogen, and treatment","volume":"12","author":"JB Parsons","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"pone.0304103.ref032","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations\u2013a review of recent developments in MRSA management and treatment","volume":"21","author":"Ali Hassoun","year":"2017","journal-title":"Crit Care"},{"key":"pone.0304103.ref033","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis, a randomized clinical trial","volume":"72","author":"M Pujol","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T17:30:40Z","timestamp":1716226240000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304103"}},"subtitle":[],"editor":[{"given":"Nosheen","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304103","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}